HCPCS code J9026: Tarlatamab injection, per 1 mg2026 Medicare rate & RVUs

Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.

What J9026 covers

Tarlatamab-dlle (Imdelltra) is an intravenous immunotherapy used for adults with extensive-stage small cell lung cancer that has progressed during or after platinum-based chemotherapy. It engages T cells and cancer cells through DLL3, prompting an immune response against the tumor. Oncology clinicians administer it by infusion, typically in a hospital outpatient department or infusion center, with step-up dosing at treatment initiation.

J9026 represents 1 mg of tarlatamab-dlle, so the HCPCS unit count corresponds to the number of milligrams administered. CMS excludes the code from the physician fee schedule under status E. When Medicare covers the drug, payment is through another method; the HCPCS pricing method identifies it as a Part B drug generally paid using CMS quarterly Average Sales Price drug pricing files. Coverage is left to the Medicare contractor’s judgment.

This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.

Where J9026 pays more and less

The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.

109 of 109 payment localities

J9026 rates by state

Office rate range in each state. Select a state to see its payment localities.

How the J9026 rate is calculated

Each of J9026’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.

Payment rules and modifiers for J9026

J9026 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.

J9026 compared with similar codes

How to choose

J9039BlinatumomabPer 1 mcg

J9039 identifies blinatumomab, not tarlatamab-dlle; the drugs have different indications and HCPCS codes.

J9022Atezolizumab injectionPer 10 mg

J9022 identifies atezolizumab per 10 mg. J9026 identifies tarlatamab-dlle per 1 mg; select the code for the drug actually administered.

J9023Avelumab injectionPer 10 mg

J9023 identifies avelumab per 10 mg, a different antineoplastic drug. J9026 is specific to tarlatamab-dlle and uses a 1 mg unit.

Codes related to J9026

Related codes aren’t interchangeable: bill the code that matches the service performed.

Where these rates come from

FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.

CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027

Open CMS sourceHow we calculate rates